Belzupacap sarotalocan is under clinical development by Aura Biosciences and currently in Phase III for Uveal Melanoma. According to GlobalData, Phase III drugs for Uveal Melanoma have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Belzupacap sarotalocan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Belzupacap sarotalocan overview
AU-011 is under development for the treatment of ocular melanoma (uveal and choroidal melanoma), non muscle invasive bladder cancer (NMIBC) (superficial bladder cancer), muscle invasive bladder cancer (MIBC), cancers of the ocular surface and other HSPG expressing cancers. It is administered as an intravitreal, suprachoroidal, intratumoral and intramural route. The therapeutic candidate is developed based on Nanosmart technology. The drug candidate is a VDC (virus like drug conjugate).
It was under development for the treatment of head and neck cancer squamous cell carcinoma.
Aura Biosciences overview
Aura Biosciences is a clinical-stage biotechnology company that develop a new standard of care across multiple cancer indications and enables broad range of solid tumors using VLPs. The company is headquartered in Boston, Massachusetts, the US.
For a complete picture of Belzupacap sarotalocan’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
